Hints and tips:
Related Special Reports
..., as well as share their experiences of health conditions....
...The group said the payments covered “appropriate home security systems”, as well as security consultancy and other services.JPMorgan chief executive Jamie Dimon received $150,645 “for the cost of residential...
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...As well as proceeds from its Covid products, Pfizer has also benefited from the spin-off of its Upjohn generics business, which combined with Mylan to form Viatris in late 2020....
...But, of course, there’s a reason why it’s widely called Shitibank; the sprawling, gormless Citi has for a v v v very long time proven adept at blithely ambling onto various rakes around the world....
...Pfizer will keep the commercialisation rights outside the US and Japan. Roivant owns 75 per cent of Telavant, while Pfizer owns 25 per cent....
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...Pfizer will spend $229 in cash per share to buy Seagen, funding the transaction through $31bn of new long-term debt, as well as short-term financing and cash....
...Last week, a verdict was passed down in the case of Walkers Snack Foods Ltd v Commissioners for His Majesty’s Revenue and Customs, with first-tier tribunal judges Anne Fairpo and Sonia Gable ruling against...
...It also reported a strong fourth quarter, with adjusted earnings of $1.14 a share, well above consensus forecasts of $1.05 a share....
...The firm had filed to launch 18 ETFs that track the performance of Tesla, Salesforce, ConocoPhillips, Boeing, Wells Fargo, Pfizer, Nike, Nvidia and PayPal, but only leveraged and inverse ETFs betting on...
...“Imagine if we get a pathogen where that [mRNA] product somehow can’t work as well as we would expect it to....
...Shares of Pfizer and rival Moderna have shed more than a fifth of their values as demand receded....
...The New Jersey pharmaceutical titan’s share price has doubled in the past five years, well ahead of the wider S&P 500 index....
...The oncology-focused biotech agreed a $43bn deal to be acquired by Pfizer....
...Justice, intend to follow through on their mission to draw a tougher line on antitrust.Still outstanding are large contested deals, including Amgen’s planned $28bn takeover of Horizon Therapeutics and Pfizer...
...The limited supply has turned Paxlovid into a popular gift among China’s well-connected....
...In March Pfizer swooped on Seagen, announcing a deal for a total enterprise value of $43bn, which was the largest pharmaceutical transaction announced since AbbVie agreed to buy Allergan in 2019....
...Illumina’s market capitalisation is roughly $33bn, about a quarter of Amgen’s and well below Pfizer’s $246bn valuation....
...The jab was well tolerated, with no safety concerns, it added....
...Novavax said on Monday it remained “well-positioned to execute on its strategy”, which includes the development of experimental flu vaccines and an Omicron-targeted Covid shot....
...Haleon, GlaxoSmithKline’s consumer healthcare venture with Pfizer, is down about 5 per cent from its July listing price....
...Pfizer said the drug shows antiviral activity against Omicron subvariants BA.1 and BA.2 in lab studies, and its structure means it is likely to be able to tackle the BA.4 and 5 subvariants as well....
...Matt Linley, Airfinity analytics’ director, said the mRNA jabs could charge more than rivals because they had performed so well and shown they can adapt quickly to develop jabs to target new variants....
...“The Keytruda patent estate really does go well beyond 2028,” said Umer Raffat, analyst at Evercore ISI....
International Edition